Cantabio Pharmaceuticals to Present at the 9th Annual Biotech Showcase in San Francisco December 15, 2016
Cantabio Pharmaceuticals to Present at 2016 Silicon Valley Bank Healthcare Capital and Connections Summit in Shanghai September 19, 2016
Cantabio Pharmaceuticals licenses Tau protein targeting therapeutic program from University of Cambridge for the potential treatment of Alzheimer’s Disease and related Dementias September 7, 2016
Cantabio Pharmaceuticals to Present Results from its DJ-1 Protein Targeting Therapeutic Programs at the 4th World Parkinson’s Congress and 3rd International Parkinson’s Disease Symposium August 18, 2016
Cantabio Pharmaceuticals and Purdue Research Foundation Sign Cooperation Agreement to Investigate the Targeting of DJ-1 Protein for Treating Parkinson’s Disease and Other Neurodegenerative Diseases July 11, 2016
Cantabio Pharmaceuticals, Purdue Research Foundation sign cooperation agreement to investigate targeting of DJ-1 protein for treating Parkinson's disease, other neurodegenerative diseases July 11, 2016
Cantabio Pharmaceuticals and University of Antioquia Collaborate to Research Company’s Therapeutic Candidates Targeting DJ-1 Protein to Treat Parkinson’s Disease June 16, 2016
Cantabio Pharmaceuticals Announces the Development of Small Molecule Chaperones of the Abeta Peptide for the Treatment of Alzheimer's Disease in Collaboration with NovAliX April 12, 2016